Format

Send to

Choose Destination
Pharmacotherapy. 2019 Sep 10. doi: 10.1002/phar.2329. [Epub ahead of print]

Systematic review of L-glutamine for prevention of vaso-occlusive pain crisis in patients with sickle cell disease.

Author information

1
Drug Information Center, Clinical Associate Professor,Department of Pharmacy Practice,D'Youville College School of Pharmacy, 320 Porter Avenue, DAC Ste 320, Buffalo, New York, 14201.
2
Department of Pharmacy Practice, University at Buffalo School of Pharmacy and Pharmaceutical Science, Buffalo, New York.
3
Clinical Assistant Professor of Internal Medicine and Pediatrics, Department of Medicine,Jacobs School of Medicine & Biomedical Sciences,Buffalo, New York.
4
D'Youville School of Pharmacy, Buffalo, New York.

Abstract

INTRODUCTION:

L-glutamine was approved by the United States Food and Drug Administration (FDA) for sickle cell disease (SCD) in 2017. Vaso-occlusive crisis (VOC) occurs in persons with SCD and is associated with acute pain episodes. This systematic review summarizes the evidence for L-glutamine in the prevention of VOC and associated pain in patients with SCD.

METHODS:

Medline, Embase, and International Pharmaceutical Abstracts were searched for records reporting on L-glutamine use in persons with SCD. Eligibility criteria identified primary reports of investigations conducted in humans who were administered L-glutamine, reported on outcomes related to VOC or associated pain, published in English, and available as full text. All relevant efficacy, safety, participant demographic data, and study method characteristics were extracted and documented. Risk-of-bias assessments were conducted using the Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-I) tool and the revised Cochrane risk-of-bias tool for randomized studies.

RESULTS:

Three studies assessing the effect of exogenous L-glutamine administration in patients with SCD met eligibility criteria, including one prospective, nonrandomized, controlled study and two prospective, randomized, controlled trials. Rate of VOC and related hospitalizations were reduced in patients receiving L-glutamine, although some conflicting results were noted between studies. L-glutamine was generally well tolerated. Limitations of one or more of the eligible studies included small sample size, nonblinding, and study groups that differed at baseline.

DISCUSSION:

L-glutamine has limited high-quality evidence supporting its use. Although L-glutamine is FDA approved for the prevention of frequent episodes of VOC pain, only one randomized controlled trial has strong evidence to support this indication. Based on the results of a systematic review, L-glutamine may be considered for patients unable to receive hydroxyurea or in addition to hydroxyurea for reduction in VOC and associated pain.

KEYWORDS:

L-glutamine; glutamine; pain crisis; sickle cell; vaso-occlusive crisis

PMID:
31505045
DOI:
10.1002/phar.2329

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center